February 14, 2023 02:54 PM ESTUpdated 06:00 PM

Law experts argue that abortion drug withdrawal would 'undermine' the approval process

Nicole DeFeudis

Editor

More than a dozen food and drug law experts argued on Wednesday that yanking the medication abortion drug mifepristone from the market would “undermine the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Law experts argue that abortion drug withdrawal would 'undermine' the approval process

Nicole DeFeudis

Editor

Sign up to read this article for free.

Regeneron buys London-based ocular biotech

A look at biotech's year of the megaround

Roche circles back to China biotech with $80M deal for lung cancer ADC

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Neumora's major depression drug flunks first of three Phase 3 trials

Law ex­perts ar­gue that abor­tion drug with­draw­al would 'un­der­mine' the ap­proval process

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Re­gen­eron buys Lon­don-based oc­u­lar biotech

A look at biotech's year of the megaround

Roche cir­cles back to Chi­na biotech with $80M deal for lung can­cer ADC

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Law experts argue that abortion drug withdrawal would 'undermine' the approval process

Regeneron buys London-based ocular biotech

Roche circles back to China biotech with $80M deal for lung cancer ADC

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Neumora's major depression drug flunks first of three Phase 3 trials